 |
 |
 |
 |
 |
 |
 |
- January 8, 2010 - EyeGate Pharma Secures $22M in Series D Venture Funding for Continued Development of EGP-437 for Dry Eye Syndrome
- October 15, 2009 - EyeGate Pharma Completes Phase II Study of EGP-437 in Patients with Anterior Uveitis
- June 3, 2009 - Eyegate Pharma Announces that EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study